Immorta Bio advances nine-amino-acid senolytic peptide against zombie cells
The company says the short peptide is designed to clear senescent cells, a target long pursued by longevity developers.
TR
By Tom Reyes · Markets Editor
Oct 23 12:49 ETSource: Longevity.Technology
The wire
- 01Immorta Bio is developing a nine-amino-acid peptide aimed at senescent cells, according to the company.
- 02Senolytics sit next to epithalon, MOTS-c and humanin on the longevity-peptide shelf that clinicians are asked about.
- 03Company claims are preclinical as described; no peer-reviewed human data or trial timeline is given.
From the source
Read at longevity.technologyImmorta Bio’s nine-amino-acid peptide aims at zombie cells
